Abstract 2127P
Background
Yoga has gained more attention worldwide in the last decade and shown the potential to improve physiological and psychological health in various disease conditions. Studies on breast cancer (BC) survivors showed mild to moderate effects within one-month to six-month on various parameters. Cancer treatment-related side effects are often related with functional as well as symptomatic scales. Therefore, we have conducted a randomized control study to find out the effect of long-term yogic intervention on symptom and functional scale in patients undergoing treatment.
Methods
This study was approved by the institutional ethics committee. The current study consisted of 96 BC stage II/III patients receiving cancer treatments who were randomly divided into two groups: Group-I (non-yoga) and Group-II (yoga). Group-II was advised to perform yoga 5 days per week for 48 weeks and was monitored regularly by video or phone calls. At different time points (T0 (baseline), T1 (16th week), T2 (32nd week), and T3 (48th week), we collected the breast cancer specific questionnaire (EORTC-BR23), which consisted of various functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and symptomatic scales (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss), and compared them between groups as well as within group.
Results
Out of 96 total patients, 82 were analyzed for T0-T3 (40 in group-I and 42 in group-II). In groups I and II, the mean age was 47.67±11.68 and 43.11±9.39, respectively. Yogic intervention resulted in a significant improvement in arm symptoms and side effects from T0 to T3 (p<0.001) and T1 to T3 (p<0.01) in group II, while group I also improved from T0 to T3 (p<0.05). The most significant difference was observed in Group-I (T0) vs. Group-II (T3). There was no significant difference observed in upset by hair loss, body image, breast symptoms, or future perspective.
Conclusions
The duration of yoga positively correlated with the systematic therapy side effects and improved their arm symptoms. This suggested that yogic intervention during therapy could be an effective complementary therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06